BioSpace News Archive

Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protection BARHEMSYS ® (amisulpride for injection) and BYFAVO ® (remimazolam for injection) join Eagle portfolio, with an estimated combined $3.1 billion per year 1 addressable market and projected annual peak sales of $275 2 million in the U.S.

31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR data.

Global agreement with Holo4Labs promises to free lab technicians from paper and laptops for more efficient lab operations with reduced errors.

BIONIK Laboratories Corp. (OTCPink: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for the fourth quarter and fiscal year 2022, ended March 31, 2022.

Immunocore Holdings plc today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022.

GNS today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined GNS as a strategic advisor.

Teva to Present Latest Data on AJOVY ® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting.

Clinscience extends Calyx’s reliable, expedited imaging services to its global pharmaceutical customers.

Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print investigational products, announced that its Annual Meeting of Stockholders will be held virtually via live webcast on Thursday, June 16, 2022 at 10:00 am EDT.

Impel Pharmaceuticals (NASDAQ: IMPL), today announced that it will present one oral presentation and three poster presentations from the pivotal, 52-week long, open-label, Phase 3 STOP 301 trial exploring the safety and exploratory efficacy of Trudhesa® (dihydroergotamine mesylate [DHE]) nasal spray (0.725 mg per spray), at the 64TH Annual American Headache Society (AHS) Scientific Meeting.